Khadija Saeed

Khadija Saeed

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

Compass (COMP) stock jumps after-hours on Q4 outlook lift and $750 mln notes plan ahead of Anywhere merger

Compass (COMP) stock jumps after-hours on Q4 outlook lift and $750 mln notes plan ahead of Anywhere merger

Compass, Inc. shares rose 9.4% to $11.84 in after-hours trading on Wednesday after the real estate brokerage flagged stronger fourth-quarter performance and detailed financing plans tied to its pending merger with Anywhere Real Estate. The stock swung between $9.90 and $12.58 during the session on volume of about 103 million shares.
Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck & Co shares edged down in after-hours trading on Wednesday after U.S. health officials updated the childhood immunization schedule and moved to a single dose for the human papillomavirus vaccine, a change that could pressure demand for Merck’s Gardasil shot. The stock was down about 0.2% at $108.60, after trading between $107.99 and $111.42 in the regular session. HHS.gov
First Solar stock slides 10% on Jefferies downgrade as 2026 orders come into focus

First Solar stock slides 10% on Jefferies downgrade as 2026 orders come into focus

Shares of First Solar fell 10.3% to $241.11 on Wednesday after Jefferies downgraded the U.S. solar panel maker to “hold” from “buy” and cut its price target to $260 from $269. The brokerage cited “limited booking visibility” for 2026 and said a hoped-for “S232” tailwind — shorthand for potential Section 232 duties that can be imposed after a Commerce Department national-security investigation — could “underwhelm investor expectations,” flagging possible carve-outs for Germany and developers moving ahead of any levies. The stock opened at $254.02 and touched $239.26 at its low; volume was about 6.2 million shares. TipRanks
AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view

AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view

AbbVie shares were down about 1% at $231.11 in after-hours trading on Wednesday after the drugmaker denied a Wall Street Journal report that it was in advanced talks to buy cancer-drug developer Revolution Medicines, saying it “is not in discussions with Revolution Medicines.” The stock had closed up 4.2% at $233.42, while Revolution shares slid 11.5% late after jumping nearly 30% earlier, with the report pointing to a valuation around $20 billion. AbbVie has spent more than $20 billion on acquisitions since 2023 as its former blockbuster Humira lost patent protection. Reuters+1
Binance rolls out 50x silver futures — what the new XAGUSDT contract means for crypto traders

Binance rolls out 50x silver futures — what the new XAGUSDT contract means for crypto traders

Binance Futures said on Wednesday it will launch a silver perpetual futures contract that lets users trade the metal with up to 50 times leverage. The USDT-margined XAGUSDT contract, which tracks the price of one troy ounce of silver in U.S. dollars, was scheduled to start trading at 10:00 UTC, and Binance said it may tweak terms such as funding fees and margins as market conditions change. Binance
8 January 2026
1 556 557 558 559 560 893
AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

Taiwan Semiconductor

NYSE: TSM 96 / 100
#2 BUY

AerCap

NYSE: AER 95 / 100
#3 BUY ON PULLBACK

Constellation Energy

NASDAQ: CEG 93 / 100
#4 BUY

Walt Disney

NYSE: DIS 90 / 100
#5 ACCUMULATE

American International Group

NYSE: AIG 87 / 100
View full portfolio
Editorial model selection. Not personalised advice.